Low Circulating Free Triiodothyronine Levels are Association with Progression Diabetic Nephropathy in Patients with Type 2 Diabetes

Abstract

Background: Diabetic nephropathy (DN) is a significant consequence of T2DM that causes
CKD and ESRD. Recent investigations have linked thyroid hormones, particularly free
triiodothyronine (FT3), to DN progression. Low FT3 levels are linked to lower outcomes in
chronic illnesses, including renal failure. This study investigated the relationship between
type 2 diabetes and low circulating free triiodothyronine levels and nephropathy development.
Methods: We enrolled ninety-eight type 2 diabetic patients. Patients with type 2 diabetes who were 18 years of age or older met the inclusion criteria. Patient interviews, medical records, and laboratory tests were used to gather data. FT3 levels were measured in blood samples, and estimated glomerular filtration rates (eGFR) and urine albumin excretion rates were used to gauge how far along DN was. The statistical analysis was done with SPSS 23.0.
Results: Of the 98 participants, 28.6% showed progression of diabetic nephropathy. Patients with low FT3 levels (<2.0 pg/mL) had a higher rate of nephropathy progression (52.9%) compared to those with normal FT3 levels (15.6%). Multivariate regression analysis revealed
that low FT3 levels were significantly associated with nephropathy progression (β = 1.47, p <
0.001) after adjusting for confounders.
Conclusion: Patients with type 2 diabetes have a substantial correlation between the development of diabetic nephropathy and low levels of free triiodothyronine in the blood.
Thyroid hormone monitoring may be essential for controlling the progression of DN.

Recommendations: To investigate the underlying mechanisms and assess the possible advantages of treatment approaches aimed at thyroid function in people with diabetes, more
research is required.